List of works - Robert L. Dow

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

scientific article

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

scientific article published on 01 May 1991

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

scientific article published on 6 August 2009

Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor ⬇️

scientific article published on September 1, 2013

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core

scientific article published on 12 August 2011

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents

scientific article

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity

scientific article

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

scientific article published on 18 March 2011

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics

scientific article (publication date: 10 February 2003)

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

scientific article (publication date: 12 January 1996)

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment

scientific article published on 6 October 2015

Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors

scientific article published on 01 July 1994

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

scientific article

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

scientific article published on 2 November 2005

PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease

scientific article published on 24 December 2020

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif

scientific article

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.

scientific article

Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.

scientific article published on 27 August 2013

Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors.

scientific article

Thyroid receptor agonists for the treatment of androgenetic alopecia.

scientific article published on 29 October 2009

Undesired versus designed enzymatic cleavage of linkers for liver targeting

scientific article published on 8 January 2014

List of works by Robert L. Dow

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor ⬇️

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment

Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors

MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.

Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.

Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors.

Thyroid receptor agonists for the treatment of androgenetic alopecia.

Undesired versus designed enzymatic cleavage of linkers for liver targeting